Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) EBIT (2022 - 2025)

Historic EBIT for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to -$47.1 million.

  • Entrada Therapeutics' EBIT fell 11724.54% to -$47.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$121.6 million, marking a year-over-year decrease of 31036.81%. This contributed to the annual value of $47.0 million for FY2024, which is 158674.89% up from last year.
  • Entrada Therapeutics' EBIT amounted to -$47.1 million in Q3 2025, which was down 11724.54% from -$46.8 million recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' EBIT registered a high of $53.4 million during Q2 2024, and its lowest value of -$47.1 million during Q3 2025.
  • Over the past 4 years, Entrada Therapeutics' median EBIT value was -$21.7 million (recorded in 2024), while the average stood at -$11.3 million.
  • Over the last 5 years, Entrada Therapeutics' EBIT had its largest YoY gain of 46527.68% in 2024, and its largest YoY loss of 25456.75% in 2024.
  • Entrada Therapeutics' EBIT (Quarter) stood at -$25.6 million in 2022, then soared by 119.18% to $4.9 million in 2023, then plummeted by 219.61% to -$5.9 million in 2024, then tumbled by 701.96% to -$47.1 million in 2025.
  • Its EBIT was -$47.1 million in Q3 2025, compared to -$46.8 million in Q2 2025 and -$21.8 million in Q1 2025.